5-Star Stocks Poised to Pop: Celgene

Based on the aggregated intelligence of  the 110,000 investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company Celgene (Nasdaq: CELG  ) has earned a coveted five-star ranking. Our data has shown that five-star stocks outperform the market by a significant margin; conversely, one-star stocks have woefully lagged the market average.

With that in mind, let's take a closer look at Celgene's business, and see what CAPS investors are saying about the stock right now.

Celgene facts

Headquarters (Founded)	Summit, New Jersey (1980)
Market Cap	$31.66 billion
Industry	Biotechnology
TTM Revenue	$1.58 billion
Management	CEO Dr. Sol Barer (since 2006) COO Robert Hugin (since 2006)
Return on Capital (avg. last three years)	7.8%
CAPS players bullish on CELG also bullish on	Google (Nasdaq: GOOG  ) Cisco Systems (Nasdaq: CSCO  ) Transocean (NYSE: RIG  )
CAPS players bearish on CELG also bearish on	Amazon.com (Nasdaq: AMZN  ) Baidu.com (Nasdaq: BIDU  ) Crocs (Nasdaq: CROX  )

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, 361 of the 374  All-Star players who have rated Celgene -- roughly 96.5% -- believe the stock will outperform the S&P 500 going forward. These All-Star bulls include FRINEDOFFOXY and Firesale, both of whom are ranked in the top 15% of our community.

In February 2007, FRINEDOFFOXY noted that Celgene is "a leader in biotech. One of the best positioned for research breakthroughs both large & small."

An earlier pitch by Firesale elaborates on that bullish attitude, educating our community about the company's top two drugs:

Since 1988 Celgene received FDA approved for Thalomid to treat leprosy-related conditions and multiple myeloma (MM). ...

In 2005, CELG announced FDA approval of Revlimid (the company's primary IMiD) to treat MDS patients with a rare chromosomal deletion. This is their leading drug, and is being studied for multiple myeloma, amyloidosis, non-Hodgkin's lymphoma, and various solid tumor cancers. ... After hitting a new 52-week high Celgene is a winner and looks to be the next Genentech. [Since this pitch, the shares remain unchanged.]

What do you think about Celgene, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 110,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.